Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch

Oncogene

Volumn 33, Issue 45, 2014, Pages 5251-5261

  Tennakoon, J B ^a   Shi, Y ^a   Han, J J ^a   Tsouko, E ^a   White, M A ^a   Burns, A R ^b   Zhang, A ^c   Xia, X ^c   Ilkayeva, O R ^d   Xin, L ^e,f   Ittmann, M M ^e,f,g   Rick, F G ^h,i   Schally, A V ^h,j   Frigo, D E ^a,c  

^a University of Houston   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Dan L Duncan Cancer Center   (United States)

^g MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

AMP activated protein kinase; androgen receptor; metabolism; peroxisome proliferator activated receptor coactivator 1 ; prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METRIBOLONE; PPARGC1A PROTEIN, HUMAN; PRKAA1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANIMAL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; GLYCOLYSIS; HUMAN; KAPLAN MEIER METHOD; KNOCKOUT MOUSE; MALE; METABOLISM; MITOCHONDRION; OXIDATIVE PHOSPHORYLATION; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ULTRASTRUCTURE; WESTERN BLOTTING; WISTAR RAT;

AMP-ACTIVATED PROTEIN KINASES; ANDROGENS; ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GLYCOLYSIS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METRIBOLONE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; PROSTATIC NEOPLASMS; RATS, WISTAR; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 85027952132     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.463     Document Type: Article

References (62)

1. Warburg O. On the origin of cancer cells. Science 1956; 123: 309–314. DOI: 10.1126/science.123.3191.309
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646–674. DOI: 10.1016/j.cell.2011.02.013
3. Ertel A, Tsirigos A, Whitaker-Menezes D, Birbe RC, Pavlides S, Martinez-Outschoorn UE et al. Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle 2012; 11: 253–263. DOI: 10.4161/cc.11.2.19006
4. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11–20. DOI: 10.1016/j.cmet.2007.10.002
5. Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE. Altered metabolism and mitochondrial genome in prostate cancer. J Clin Pathol 2006; 59: 10–16. DOI: 10.1136/jcp.2005.027664
6. Costello LC, Franklin RB, Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 2005; 5: 143–153. DOI: 10.1016/j.mito.2005.02.001
7. Bhalla K, Hwang BJ, Dewi RE, Ou L, Twaddel W, Fang HB et al. PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res 2011; 71: 6888–6898. DOI: 10.1158/0008-5472.CAN-11-1011
8. Skrtic M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2011; 20: 674–688. DOI: 10.1016/j.ccr.2011.10.015
9. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25: 460–470. DOI: 10.1101/gad.2016311
10. Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, Kim SH et al. Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem 2010; 285: 26558–26569. DOI: 10.1074/jbc.M109.063255
11. Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, McDonnell DP. The metabolic regulator ERRalpha, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell 2011; 20: 500–510. DOI: 10.1016/j.ccr.2011.08.023
12. Cormio A, Guerra F, Cormio G, Pesce V, Fracasso F, Loizzi V et al. The PGC-1alpha-dependent pathway of mitochondrial biogenesis is upregulated in type I endometrial cancer. Biochem Biophys Res Commun 2009; 390: 1182–1185. DOI: 10.1016/j.bbrc.2009.10.114
13. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012; 148: 651–663. DOI: 10.1016/j.cell.2011.12.028
14. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci USA 2005; 102: 5992–5997. DOI: 10.1073/pnas.0502267102
15. Stoss O, Werther M, Zielinski D, Middel P, Jost N, Ruschoff J et al. Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 2008; 11: 166–172. DOI: 10.1038/sj.pcan.4501001
16. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011; 10: 4047–4064. DOI: 10.4161/cc.10.23.18151
17. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25: 717–729. DOI: 10.1101/gad.2016111
18. Oyama N, Miller TR, Dehdashti F, Siegel BA, Fischer KC, Michalski JM et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 2003; 44: 549–555.
19. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999; 36: 31–35. DOI: 10.1159/000019923
20. Pillarsetty N, Punzalan B, Larson SM. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer. J Nucl Med 2009; 50: 1709–1714. DOI: 10.2967/jnumed.109.064212
21. Yu EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB et al. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med 2011; 36: 192–198. DOI: 10.1097/RLU.0b013e318208f140
22. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11–22. DOI: 10.1016/j.ccr.2010.05.026
23. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15: 4792–4798. DOI: 10.1158/1078-0432.CCR-08-2660
24. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33–39. DOI: 10.1038/nm972
25. Frigo DE, Howe MK, Wittmann BM, Brunner AM, Cushman I, Wang Q et al. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res 2011; 71: 528–537. DOI: 10.1158/0008-5472.CAN-10-2581
26. Karacosta LG, Foster BA, Azabdaftari G, Feliciano DM, Edelman AM. A regulatory feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the androgen receptor in prostate cancer progression. J Biol Chem 2012; 287: 24832–24843. DOI: 10.1074/jbc.M112.370783
27. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L et al. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. Embo J 2011; 30: 2719–2733. DOI: 10.1038/emboj.2011.158
28. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733–741. DOI: 10.1158/1535-7163.MCT-08-0631
29. Jung SN, Park IJ, Kim MJ, Kang I, Choe W, Kim SS et al. Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp Cell Res 2009; 315: 2433–2441. DOI: 10.1016/j.yexcr.2009.05.018
30. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature 2012; 485: 661–665. DOI: 10.1038/nature11066
31. Laderoute KR, Amin K, Calaoagan JM, Knapp M, Le T, Orduna J et al. 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006; 26: 5336–5347. DOI: 10.1128/MCB.00166-06
32. Wang J, Cai Y, Shao LJ, Siddiqui J, Palanisamy N, Li R et al. Activation of NF-{kappa}B by TMPRSS2/ERG fusion isoforms through toll-like receptor-4. Cancer Res 2011; 71: 1325–1333. DOI: 10.1158/0008-5472.CAN-10-2210
33. Agoulnik IU, Vaid A, Bingman WE 3rd, Erdeme H, Frolov A, Smith CL et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005; 65: 7959–7967. DOI: 10.1158/0008-5472.CAN-04-3541
34. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 2011; 71: 572–582. DOI: 10.1158/0008-5472.CAN-10-2314
35. Moon JS, Jin WJ, Kwak JH, Kim HJ, Yun MJ, Kim JW et al. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem J 2011; 433: 225–233. DOI: 10.1042/BJ20101104
36. Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res 2010; 30: 369–374.
37. Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate 2005; 63: 316–323. DOI: 10.1002/pros.20177
38. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 230–234. DOI: 10.1038/sj.pcan.4500879
39. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910–914. DOI: 10.1038/nature07762
40. Jager S, Handschin C, St-Pierre J, Spiegelman BM. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 2007; 104: 12017–12022. DOI: 10.1073/pnas.0705070104
41. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004; 64: 8867–8875. DOI: 10.1158/0008-5472.CAN-04-2938
42. Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB et al. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71: 736–747. DOI: 10.1002/pros.21289
43. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M et al. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 2011; 108: 3755–3760. DOI: 10.1073/pnas.1018086108
44. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209–221. DOI: 10.1016/S1535-6108(03)00215-0
45. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4: 223–238. DOI: 10.1016/S1535-6108(03)00197-1
46. Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393–406. DOI: 10.1016/j.ccr.2005.10.001
47. Arredouani MS, Lu B, Bhasin M, Eljanne M, Yue W, Mosquera JM et al. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer. Clin Cancer Res 2009; 15: 5794–5802. DOI: 10.1158/1078-0432.CCR-09-0911
48. Chandran UR, Ma C, Dhir R, Bisceglia M, Lyons-Weiler M, Liang W et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. BMC Cancer 2007; 7: 64. DOI: 10.1186/1471-2407-7-64
49. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66: 4011–4019. DOI: 10.1158/0008-5472.CAN-05-3055
50. Tamura K, Furihata M, Tsunoda T, Ashida S, Takata R, Obara W et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67: 5117–5125. DOI: 10.1158/0008-5472.CAN-06-4040
51. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012; 21: 297–308. DOI: 10.1016/j.ccr.2012.02.014
52. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Tatsugami K, Kuroiwa K et al. Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol 2010; 24: 114–127. DOI: 10.1210/me.2009-0302
53. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 2012; 15: 827–837. DOI: 10.1016/j.cmet.2012.05.001
54. Sahin E, Colla S, Liesa M, Moslehi J, Muller FL, Guo M et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 2011; 470: 359–365. DOI: 10.1038/nature09787
55. Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012; 148: 896–907. DOI: 10.1016/j.cell.2012.01.039
56. O'Mahony F, Razandi M, Pedram A, Harvey BJ, Levin ER. Estrogen modulates metabolic pathway adaptation to available glucose in breast cancer cells. Mol Endocrinol 2012; 26: 2058–2070. DOI: 10.1210/me.2012-1191
57. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 2004; 321: 161–167. DOI: 10.1016/j.bbrc.2004.06.133
58. Irrcher I, Ljubicic V, Kirwan AF, Hood DA. AMP-activated protein kinase-regulated activation of the PGC-1alpha promoter in skeletal muscle cells. PLoS One 2008; 3: e3614. DOI: 10.1371/journal.pone.0003614
59. Klimcakova E, Chenard V, McGuirk S, Germain D, Avizonis D, Muller WJ et al. PGC-1alpha promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. Cancer Res 2012; 72: 1538–1546. DOI: 10.1158/0008-5472.CAN-11-2967
60. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45–56. DOI: 10.1016/j.cmet.2007.10.013
61. Jin C, McKeehan K, Wang F. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate 2003; 57: 160–164. DOI: 10.1002/pros.10283
62. Zhang B, Chen H, Zhang L, Dakhova O, Zhang Y, Lewis MT et al. A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis. Oncogene (e-pub ahead of print 15 July 2013; doi:10.1038/onc.2013.281). DOI: 10.1038/onc.2013.281